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onary stent implantation is associated with higher risk for bleeding.
Second-generation drug-eluting stents (G2-DES), cobalt-chromium
everolimus-eluting stent (CoCr-EES) in particular, are reported to
have lower risk for stent thrombosis (ST) compared with ﬁrst gener-
ation DES or bare-metal stents. Therefore, the optimal DAPT duration
after CoCr-EES implantation could be shorter than 6-12 months
currently recommended in the guidelines. However, there has been
no prospective study evaluating DAPT duration shorter than 6 months
after CoCr-EES implantation.
METHODS STOPDAPT study is a prospective multicenter single-arm
registry enrolling patients who agreed to follow the 3-month DAPT
protocol (discontinuation of clopidogrel at 2- to 4-month and aspirin
monotherapy thereafter) after successful CoCr-EES implantation. The
primary endpoint was a composite of cardiovascular (CV) death,
myocardial infarction (MI), stroke, deﬁnite ST and TIMI major/minor
bleeding at 1-year. As a historical comparison group, we selected the
CoCr-EES group in the RESET trial comparing CoCr-EES with sirolimus-
eluting stent conducted in 2010, where nearly 90% of patients had
continued DAPT at 1-year. With the 6.6% of performance goal based on
the event rate of 4.4% in the RESET trial, a total of 1500 patients would
yield 95% power at a level of one-sided type 1 error of 0.025.
RESULTS Between September 2012 and October 2013, a total of 1525
patients were enrolled in the study from 58 participating centers across
Japan, and 1-year follow-up was completed in 1519 patients (99.6%).
Thienopyridine was discontinued within 4-month in 1444 patients
(94.7%). The event rates beyond 3-month were very low (CV death:
0.5%, MI: 0.1%, deﬁnite/probable ST: 0%, stroke: 0.7%, and TIMI ma-
jor/minor bleeding: 0.8%). Cumulative 1-year incidence of the primary
endpoint was 2.8% (Upper 97.5% conﬁdence interval [CI] 3.6%), which
was lower than the pre-deﬁned performance goal of 6.6% (P<0.0001).
Compared to CoCr-EES group in the RESET trial, cumulative incidence
of the primary endpoint tended to be lower in the STOPDAPT than in
the RESET (2.8% versus 4.0%, P¼0.06) and adjusted hazard ratio was
0.64 (95%CI 0.42-0.95, P¼0.03). The cumulative incidence of deﬁnite/
probable ST was lower in the STOPDAPT than in the RESET (0 patient
[0%] versus 5 patients [0.3%], P¼0.03).
CONCLUSIONS Stopping DAPT at 3-month after CoCr-EES implanta-
tion was at least as safe as the prolonged DAPT regimen adopted in the
previous randomized trial.
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in ST elevated myocardial infarction. The prevalence of very elderly
patients (> 75 years) undergoing primary angioplasty is progressively
increasing as population is ageing. The beneﬁt of the new generation
drug-eluting stents over bare metal stents in terms of safety and efﬁ-
cacy is unknown for this important subgroup of patients in this setting.
METHODS Retrospective consecutive registry conducted in 31 centers
of patients > 75 years with ST elevation myocardial infarction un-
dergoing primary angioplasty.
RESULTS A total of 3,126 pts have been included, 2,132 (68.2%) treated
with BMS and 994 (31.8%) treated with new generation DES. After exclu-
sion of patients presenting with cardiogenic shock or requiring cardiac
surgery for mechanical complications (14%) a propensity score matching
was performed yielding two comparable groups of 580 patients each with
well- balanced baseline clinical or angiographic characteristics. Outcomes
at 12 months were: cardiac death and MI 10.2% with BMS and 5.2% with
DES (p¼0.01), TLR was 3.8% with BMS and 1.5% with DES (p¼0.04), deﬁ-
nite or probable thrombosis 4.3% with BMS and 2.4% with DES (p¼0.06),
deﬁnite thrombosis 3.7% with BMS and 1.3% with DES (p¼0.03) and
bleeding BARC > 2 0.7% with BMS and 1.2% with DES (p¼0.3).
CONCLUSIONS In this registry of patients over 75 years undergoing
primary angioplasty, most were treated with BMS. After propensity
score matching clinical outcomes were signiﬁcantly better in those
treated with new DES without signiﬁcant increase in severe bleeding
events in follow up.
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BACKGROUND Percutaneous intervention of distal bifurcation un-
protected left main coronary arteries (UPLMCA) are technically
demanding with less favorable outcomes. The optimal treatment
strategy to improve long-term outcomes is uncertain.
METHODS Studies comparing simple approach (provisional stenting)
versus complex stenting (elective two stent technique) were consid-
ered for inclusion. A search strategy using Medline, Embase, Cochrane
database and the proceedings of the international meetings were
included. Information about study design, inclusion criteria and
sample characteristics were extracted. Meta-analysis of pooled event
rates was compared between these two stenting approaches.
RESULTS 16 studies including 5978 patients who were treated with
simple versus complex bifurcation stenting for UPLMCA bifurcations
were analyzed. There were no differences in the rates of myocardial
infarction (OR 0.81, CI 0.15-4.2), stent thrombosis (OR 0.8, CI 0.2-1.7),
target vessel revascularization (OR 0.4, CI 0.6-2.7) or mortality (OR
0.92, CI 0.3-2.8) between simple versus complex stenting approaches
at 1 year. However, at 5 years of follow-up there was a signiﬁcant
difference in the rates of target vessel revascularization (OR 0.4, CI
0.3-0.7, p¼0.001) favoring the simple approach. There was no differ-
ence in the mortality (OR 0.94, CI 0.75-1.19), stent thrombosis (OR
0.83, 0.32-2.1) or myocardial infarction (OR 1.16, CI 0.7-1.7) using
either approach at 5 years of follow-up.
CONCLUSIONS Percutaneous intervention for UPLMCA should favor
a simple approach over complex approach to optimize long-term
outcomes.
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BACKGROUND Stent fracture (SF) after drug-eluting stent implanta-
tion has been reported to be associated with in-stent restenosis (ISR),
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aimed to assess the long-term clinical and angiographic impact of SF
on Xience everolimus-eluting stent (EES) and Nobori biolimus-eluting
stent (BES) implantation.
METHODS From 2010 to 2013, 3246 lesions (1783 patients) were
treated with EES and 1618 lesions (986 patients) with BES, in which
follow-up angiography was performed within one year after index
procedure. SF was deﬁned as the separation of stent segments or stent
struts at follow-up angiography. The mid-term angiography was per-
formed at 8 months and the late-term at 20 months. ISR was deﬁned
as more than 50% restenosis. Late catch-up phenomenon was deﬁned
as ISR, excluding that within one year after index procedure.
RESULTS SF was observed in 1.7% (56/3246) of the lesions treated
with EES and 4.4% (72/1618) with BES. The median follow-up duration
of the study population was 1028 days (the ﬁrst and third quarters,
838 and 1275 days). The mid-term restenosis rate showed no signiﬁ-
cant difference between the EES and BES groups (40.7% versus 30.6%,
p¼0.26). The late catch-up phenomenon rate was signiﬁcantly lower
in the BES group (18.2% versus 2.4%, p¼0.04). Very late stent
thrombosis was none in the EES group, on the other hand, occurred in
one patient in the BES group. The three-year cumulative rates of any
TLR did not signiﬁcantly differ between the 2 groups (44.8% versus
29.7%, p¼0.07). A landmark analysis of the cumulative rates of any
TLR within and beyond one year is shown in the ﬁgure.
CONCLUSIONS The long-term clinical impact of SF could be different
between EES and BES implantation.
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BACKGROUND In second generation DES era, in-stent restenosis (ISR)
is not commonly seen but is still encountered occasionally. The
pathophysiology and mechanism of ISR after second generation DES
implantation have not been fully clariﬁed.
METHODS Patients who underwent follow-up coronary angio-
graphy (CAG) after ﬁrst (Cypher and Taxus) and second generationDES (Nobori, Promus Element, Resolute Integrity, and Xience) im-
plantation were examined. The ﬁrst scheduled CAG was performed at
six to nine months after percutaneous coronary intervention (PCI) and
the second at 18 to 24 months after PCI. ISR was deﬁned as lesions
more than 75% diameter stenosis at follow-up CAG. Optical coherence
tomography (OCT) was performed at the time of revascularization to
ISR. Then OCT imaging of second generation DES ISR of early (<1 year)
and late ( 1 year) phase were compared with ﬁrst generation DES ISR,
retrospectively.
RESULTS From April 2008 to January 2010, ﬁrst generation DES were
implanted in 805 lesions. From January 2011 to December 2014, sec-
ond generation DES were implanted in 1269 lesions in our hospital.
ISR rate were signiﬁcantly lower in second generation DES ISR (9.6%
(N¼77) vs 4.0% (N¼51), p<0.05). In qualitative OCT assessment of
second generation DES ISR in total, each ratio of homogeneous,
layered, heterogeneous, lipid rich attenuation, calciﬁed nodule tissue
morphologies were 54.0% and 16.2%, 18.9%, 5.4%, and 5.4% respec-
tively. Compared with ﬁrst generation DES ISR, both in early and late
ISR cases, homogeneous morphology was signiﬁcantly higher in sec-
ond generation DES ISR (61.1% vs 36.0%, and 47.3% vs 8.0%,
respectively, p<0.05).
CONCLUSIONS Homogeneous tissue morphology assessed by OCT
was more frequently found in second generation DES ISR than ﬁrst
generation DES ISR, especially in early phase (<1 year). This ﬁnding
suggests that neointimal hyperplasia is main mechanism in second
generation DES early ISR and arterial healing process is smooth like
bare metal stents implantation.
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BACKGROUND The thin-strut, everolimus-eluting, platinum chro-
mium PROMUS Element stent (Boston Scientiﬁc, Marlborough MA)
has shown favorable early outcomes up to 4 years post-implantation
for the treatment of de novo long lesions or lesions in small-caliber
vessels, but long-term follow-up has not been previously reported.
METHODS PLATINUM SV and LL are prospective, single-arm, multi-
national studies that enrolled patients with angina pectoris or docu-
mented silent ischemia and a single de novo native coronary artery
target lesion. PLATINUM SV enrolled 94 subjects with baseline vessel
diameter 2.25 mm to <2.50 mm and lesion length 28 mm, and
PLATINUM LL enrolled 102 patients with a target lesion >24
to 34 mm long with vessel diameter 2.50 to 4.25 mm. Follow-up
was performed for 5 years.
RESULTS Patients were predominantly male (SV: 72.3%, LL: 62.7%)
and approximately one third had diabetes (SV: 42.6%, LL: 30.0%). The
mean baseline reference vessel diameter (RVD) in SV was 2.0  0.3 mm
and lesion length was 14.2  7.0 mm. For the LL study, RVD was 2.6 
0.4 and mean lesion length was 24.4  8.2 mm. The primary endpoint,
1-year target lesion failure (TLF,; cardiac death, myocardial infarction
(MI) related to the target vessel, ischemia-driven target lesion revas-
cularization [TLR]), was 2.4% for SV and 3.2% for LL, both signiﬁcantly
less than prespeciﬁed performance goals (P<0.001 for each). At 5 years,
TLF, TLR, cardiac death, MI and ARC stent thrombosis (ST) had
occurred in 6 (7.0%), 3 (3.6%), 5 (5.9%), 2 (2.4%), and 0 (0%) patients
respectively in the SV trial and TLF, TLR, cardiac death, MI and ARC
stent thrombosis (ST) had occurred in 13 (13.6%), 7 (7.5%), 5 (5.9%), 1
(1.3%), and 0 (0%) patients respectively in the LL trial.
